Antonio Olivieri to replace retiring Guy Braunstein as Idorsia CMO

22 March 2024
idorsia_building_large

Guy Braunstein, who has served as Idorsia’s (SIX: IDIA) chief medical officer (CMO) since 2022, will retire at the end of this month.

Dr Braunstein has also been head of global clinical development and a member of the Idorsia executive committee since the creation of the Swiss biopharma company.

"We already have the ideal candidate to succeed Guy from within our ranks"He will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology